Last month, the FDA granted 501(k) clearance to LiDCO to market its new advanced hemodynamic monitoring platform.
The device, named LiDCOunity v2, is used to monitor the amount of blood flowing in the body and to ensure vital organs are receiving the appropriate amount of oxygen through the titration of fluid and drug management.
“The clearance by the FDA means that medical institutions within the United States now have the opportunity to benefit from the next generation of